For UK pharmaceutical and life sciences leaders
Your HCP engagement budget is funding inbox deletions, not clinical conversations
With HCP engagement across pharma digital channels in steady decline, and most practitioners interacting with only a handful of companies, broad-reach campaigns are delivering noise, not influence.
Two minutes. Solva follows up with specific precision engagement options.
A 2024 Veeva Systems study found HCP engagement with pharma field force and online channels has fallen to 53%, with 62% of engaging HCPs interacting with only three or fewer companies - a significant consolidation of attention.
Frequently asked questions
Why does this problem persist?
HCP engagement with pharma digital channels has fallen to 53% in 2024, and of those still engaging, 62% interact with only three or fewer companies. Generic email blasts, rep-pushed PDFs, and webinars without clinical relevance are actively damaging brand perception among time-poor doctors.
What is the cost of leaving it unaddressed?
A £3m HCP engagement programme generating 2% open rates and no measurable prescribing uplift is effectively wasted spend. Precision engagement programmes targeting the right 500 HCPs outperform broad campaigns of 10,000 at a fraction of the cost. (Veeva Systems, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.